Takeda Pharmaceutical Company Limited Share Price NYSE
Stocks
TAK
US8740602052
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Cboe BZX
09:32:58 05/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 17.84 USD | -0.08% |
|
-5.69% | +14.34% |
| 30/09 | Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading | MT |
| 30/09 | Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial | MT |
| Market Cap | 9,00400Cr 5.71TCr 5.07TCr 4.73TCr 4.32TCr 8.14TCr 5,48800Cr 8.21TCr 57TCr 22TCr 2,80600Cr 21TCr 21TCr | P/E 2027 * |
44.6x | P/E 2028 * | 28.4x |
|---|---|---|---|---|---|
| Enterprise Value | 12,91100Cr 8.19TCr 7.27TCr 6.79TCr 6.19TCr 12TCr 7,86900Cr 12TCr 82TCr 32TCr 4,02300Cr 31TCr 30TCr | EV / Sales 2027 * |
2.74x | EV / Sales 2028 * | 2.65x |
| Free-Float |
99.25% | Yield 2027 * |
3.62% | Yield 2028 * | 3.7% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| TAK | Delayed | |
CBOE
| TAK | Real-time | |
|
London S.E.
| 0A87 | Delayed | |
|
Deutsche Boerse AG
| TKDA | Delayed | |
|
Tradegate
| TKDA | Real-time | |
|
Börse Stuttgart
| TKDA | Delayed | |
|
Boerse Muenchen
| TKDA | Real-time |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | -0.08% | ||
| 1 week | -5.69% | ||
| Current month | -2.01% | ||
| 1 month | -2.70% | ||
| 3 months | +5.54% | ||
| 6 months | -2.17% | ||
| Current year | +14.34% |
| 1 week | 17.75 |  | 18.58 |
| 1 month | 17.75 | | 19.1 |
| Current year | 14.84 | | 19.1 |
| 1 year | 12.99 | | 19.1 |
| 3 years | 12.58 | | 19.1 |
| 5 years | 12.28 | | 19.1 |
| 10 years | 12.28 | | 31.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.08% | -5.69% | - | - | 5.71TCr | |
| +0.54% | -2.96% | +36.05% | +112.32% | 1,01900Cr | |
| -0.84% | -6.75% | +34.78% | +61.38% | 62TCr | |
| +0.04% | -1.34% | +14.13% | +78.17% | 46TCr | |
| -3.15% | -6.11% | +57.21% | +34.75% | 36TCr | |
| +0.93% | -1.83% | +20.98% | +41.43% | 33TCr | |
| +0.12% | -4.05% | +10.09% | +33.53% | 27TCr | |
| -0.89% | -5.83% | -7.56% | +7.91% | 24TCr | |
| -0.54% | -4.42% | +35.88% | +50.76% | 22TCr | |
| -0.68% | -5.53% | +26.61% | +92.50% | 18TCr | |
| Average | -0.53% | -3.54% | +25.35% | +56.97% | 41.08TCr | |
| Weighted average by Cap. | -0.37% | -3.54% | +28.55% | +68.51% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,70400Cr 2.98TCr 2.65TCr 2.47TCr 2.25TCr 4.25TCr 2,86700Cr 4.29TCr 30TCr 12TCr 1,46600Cr 11TCr 11TCr | 4,79400Cr 3.04TCr 2.7TCr 2.52TCr 2.3TCr 4.33TCr 2,92200Cr 4.37TCr 31TCr 12TCr 1,49400Cr 11TCr 11TCr |
| Net income | 20TCr 124.58Cr 110.69Cr 103.31Cr 94Cr 177.6Cr 12TCr 179.25Cr 1.25TCr 484.48Cr 6.12TCr 467.75Cr 457.59Cr | 32TCr 204.62Cr 181.8Cr 169.68Cr 154.66Cr 291.69Cr 20TCr 294.4Cr 2.05TCr 795.71Cr 10TCr 768.23Cr 751.55Cr |
| Net Debt | 3,90700Cr 2.48TCr 2.2TCr 2.05TCr 1.87TCr 3.53TCr 2,38100Cr 3.56TCr 25TCr 9.63TCr 1,21700Cr 9.3TCr 9.1TCr | 3,70200Cr 2.35TCr 2.09TCr 1.95TCr 1.77TCr 3.35TCr 2,25700Cr 3.38TCr 24TCr 9.13TCr 1,15400Cr 8.81TCr 8.62TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | $17.84 | -0.14% | 6,66,860 |
| 02/26/02 | $17.86 | 0.00% | 21,32,769 |
| 01/26/01 | $17.86 | -1.81% | 24,03,648 |
| 30/26/30 | $18.19 | -1.73% | 21,02,758 |
| 29/26/29 | $18.51 | -2.06% | 24,15,171 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TAK Stock
Select your edition
All financial news and data tailored to specific country editions
